Categories: News

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference

SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief executive officer, Dr. Keting Chu, M.D., Ph.D., will present at the 2nd Global IR@JPM Conference on Thursday, January 20, 2022 in the biotech track to be held 7:30 – 9:30 p.m. ET.

Dr. Chu will provide an overview of the company, including BlueJay’s two therapeutic approaches with potential high rate of functional cure for HBV infections — its best-in-class anti-HBsAg monoclonal antibody approach and novel, first-in-class HBsAg inhibitor program — its preeminent management team with a proven track record in anti-infectives, strong patent position and backing by top healthcare investors.

To access the live webcast, please visit https://www.eventbrite.com/e/2022-global-ir-jpm-virtual-demo-day-tickets-220953005387.

About BlueJay Therapeutics
BlueJay Therapeutics is a private biopharmaceutical company focused on cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. BlueJay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. For more information on BlueJay, please visit the company’s website at www.bluejaytx.com.

Contact:
Alexandra Santos
asantos@wheelhouselsa.com

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

3 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

6 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

6 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

6 hours ago